Last reviewed · How we verify
metformin, glyburide and glargine
This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and glargine provides basal insulin coverage.
This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and glargine provides basal insulin coverage. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin, glyburide and glargine |
|---|---|
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Drug class | Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin) |
| Target | Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases gluconeogenesis and improves insulin sensitivity. Glyburide is a sulfonylurea that stimulates beta cells to release insulin. Glargine is a long-acting basal insulin analog that provides steady-state insulin levels. Together, they target multiple pathways of hyperglycemia in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (metformin)
- Weight gain
- Lactic acidosis (metformin, rare)
- Injection site reactions (glargine)
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients (PHASE3)
- A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus (PHASE3)
- Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment (PHASE3)
- Insulin Glargine in Type 2 Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: